These data are easily available from the \"Healthcare Cost and Utilization Project (HCUP)\" and can be obtained after completing an on-line Data Use Agreement training session and signing a Data Use Agreement. The contact information for requesting the data is as follows: HCUP Central Distributor Phone: (866) 556-4287 (toll-free) Fax: (866) 792-5313 E-mail: <HCUPDistributor@ahrq.gov>.

Introduction {#sec004}
============

The opioid epidemic in the U.S. is a concern for providers, hospitals, policy-makers and the public \[[@pone.0229174.ref001]--[@pone.0229174.ref003]\]. The opioid epidemic is associated with significant mortality with calls for action to end the epidemic \[[@pone.0229174.ref004],[@pone.0229174.ref005]\]. Based on national vital statistics data, the Centers for Disease Control (CDC) reported that 28,647 opioid-related deaths in 2014 that increased to 33,091 in 2015 (16% increase) \[[@pone.0229174.ref001]\], and to 42,249 deaths in 2016 (47% increase) \[[@pone.0229174.ref006]\]. The opioid overdose death rate increased from 2000 to 2014 \[[@pone.0229174.ref003]\] and continued the upward trend, increasing from 9.0 per 100,000 in 2014 to 10.4 in 2015 \[[@pone.0229174.ref001]\].

In addition to examining opioid use disorder (OUD)-related mortality, hospitalizations associated with OUD can help us better understand the opioid epidemic. A recent study of U.S. national inpatient sample (NIS) documented that nearly half a million hospitalizations yearly included a diagnosis of OUD (in any position, primary or secondary) \[[@pone.0229174.ref007]\]. Regional and demographic differences exist in prescription opioid and heroin-related overdose hospitalizations \[[@pone.0229174.ref008]\]. The Centers for Disease Control (CDC) issued a guideline to reduce the overutilization of prescription opioid use as a potential solution to the opioid epidemic \[[@pone.0229174.ref009]\]. Various state and federal agencies, including the drug enforcement agencies, have been monitoring narcotic prescription patterns \[[@pone.0229174.ref010]\].

Due to the limited data on hospitalizations for OUD without opioid overdose, detoxification or rehabilitation services, we aimed to examine hospitalizations related to this clinical problem. We examined time-trends in the OUD hospitalizations and the associated healthcare utilization and mortality, and assessed the factors associated with healthcare utilization and mortality during the OUD-associated hospitalizations.

Materials and methods {#sec005}
=====================

Data source {#sec006}
-----------

We included discharges from the Healthcare Cost and Utilization Project's (HCUP) National Inpatient Sample (NIS) from 1998 to 2016. The NIS is a 20% stratified sample of hospital discharges, designed for creating national estimates of all hospitalizations in the U.S. The NIS changed design in 2012 from a 20% sample of hospitals to a 20% sample of discharges from hospitals. We used the recommended trend weights from the HCUP documentation to allow analyses across multiple years. The University of Alabama at Birmingham's Institutional Review Board approved this study (X120207004) and waived the need for informed consent for this database study since these national data are de-identified. All investigations were conducted in conformity with ethical principles of research.

Study cohort {#sec007}
------------

We identified hospitalizations for OUD based on the presence of any of the following International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic codes for opioid dependence, abuse, or poisoning in the primary diagnosis position, as by the Agency for Healthcare Research and Quality \[[@pone.0229174.ref011]\]: ICD-9-CM: 304.0x, 304.7x, 305.5x, 965.0x, E850.0, E935.0, F111.xxx, F112.xxx, T40.1X1x-4x,T40.2X1x-4x, or T40.3X1x-4x. We excluded hospitalizations with ICD-9-CM diagnostic or procedure codes corresponding to drug/alcohol counseling or rehabilitation/detoxification including diagnostic codes 304.03, 304.73, 305.53, F11.11xx, or F11.21xx and procedure codes 94.45, 94.64--94.69, HZ2xxxx-3xxxx, HZ4xxxx, HZ5xxxx-6xxxx, HZ81xxx-82xxx, HZ84xxx-86xxx, HZ88xxx-89xxx, HZ91xxx-92xxx, HZ94xxx-96xxx, HZ98xxx-99xxx. This approach has been previously used by Peterson et al. \[[@pone.0229174.ref007]\]

Outcomes {#sec008}
--------

Study outcomes were index hospitalization healthcare utilization and inpatient mortality. We assessed the length of hospital stay (above/below median), the total hospital charges in U.S. dollars (above/below median for each year) and the discharge disposition, i.e., to home vs. a rehabilitation facility, which included short- or long-term care hospital, skilled nursing facility, intermediate care facility, or a certified nursing facility. We also assessed the inpatient mortality during the index hospitalization.

We assessed several important covariate and potential confounders including socio-demographics (age, sex, race/ethnicity, income \[in quartiles\]), comorbidity (Deyo-Charlson comorbidity index, a validated measure that included 17 comorbidities, based on the presence of ICD-9-CM codes \[[@pone.0229174.ref012]\], categorized as 0, 1 and ≥2), insurance payer (Medicare, Medicaid, private, self-pay or other), and hospital characteristics. We categorized hospital location/teaching status as rural, urban non-teaching or urban teaching hospital; hospital bed size as small, medium or large, using the NIS cut-offs that vary by the year; and hospital region as Northeast, Midwest, South, and West.

Statistical analyses {#sec009}
--------------------

We assessed summary statistics for the study cohort. We examined the time-trends by examining the rates of hospitalization for OUD as the primary diagnosis from 1998 to 2016 per 100,000 NIS claims. Inpatient mortality rates were similarly assessed over time for those hospitalized with OUD per 100,000 NIS claims and per 100,000 OUD claims.

We examined healthcare utilization outcomes over time. We performed separate multivariable-adjusted logistic regression analyses to assess the factors associated with each OUD hospitalization-related healthcare utilization outcome, i.e., the total hospital charges above/below the median, discharge to a rehabilitation facility vs. home, the length of hospital stay above/below the median and inpatient mortality. Models included all covariates and potential confounders of interest described in the section above. We calculated the odds ratios (OR) and 95% confidence intervals (CI).

Patient and public involvement {#sec010}
------------------------------

There was no direct patient involvement in the development of the study question or the execution of the study.

Results {#sec011}
=======

Study cohort characteristics {#sec012}
----------------------------

For the study period from 1998 to 2016, we estimated a total of 781,767 OUD hospitalizations. The mean age was 43.7 years (standard error, 0.1), 52% were male, 67% White, and about a quarter each had Medicare, Medicaid or private insurance payer ([Table 1](#pone.0229174.t001){ref-type="table"}). Fifty-four percent of people admitted for OUD were 45 years or younger. The majority (60%) were relatively healthy with a Deyo-Charlson score of zero. OUD hospitalizations were the highest in the lowest income classes; 30% in the first quartile and 27% in the second income quartile with the other quartiles near 20% each. We found that 2.4% of people hospitalized primarily for OUD died during hospitalization and 9.9% left against medical advice ([Table 1](#pone.0229174.t001){ref-type="table"}).

10.1371/journal.pone.0229174.t001

###### Characteristics of people with opioid use disorder (OUD)[\*](#t001fn001){ref-type="table-fn"} hospitalizations in the U.S. from 1998--2016.

![](pone.0229174.t001){#pone.0229174.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  N (%), unless specified otherwise                                                     Primary OUD-hospitalizations\
                                                                                        N, projected[\*\*](#t001fn002){ref-type="table-fn"} = 781,767
  ------------------------------------------------------------------------------------- ---------------------------------------------------------------
  **Age, Mean (SE); median**                                                            43.7 (0.10); 42.7

  **Age category, in years**                                                            

   \<34                                                                                 248,077 (31.74%)

   34--45                                                                               177,702 (22.74%)

   \>45--55                                                                             167,100 (21.38%)

   \>55                                                                                 188,645 (24.14%)

  **Sex**                                                                               

   Male                                                                                 407,778 (52.20%)

   Female                                                                               373,377 (47.80%)

  **Race**                                                                              

   White                                                                                520,536 (66.59%)

   Black                                                                                65,868 (8.43%)

   Hispanic                                                                             48,157 (6.16%)

   Other/missing                                                                        147,149 (18.82%)

  **Deyo-Charlson Score**                                                               

   0                                                                                    471,282 (60.28%)

   1                                                                                    164,829 (21.08%)

   ≥2                                                                                   145,656 (18.63%)

  **Hospital Location/Teaching**                                                        

   Rural                                                                                88,052 (11.55%)

   Urban nonteaching                                                                    315,210 (41.35%)

   Urban teaching                                                                       359,059 (47.10%)

  **Insurance**                                                                         

   Medicaid                                                                             222,798 (28.58%)

   Medicare                                                                             212,004 (27.19%)

   Other                                                                                42,709 (5.48%)

   Private                                                                              179,884 (23.07%)

   Self                                                                                 122,215 (15.68%)

  **Income Category**                                                                   

   First quartile                                                                       225,968 (29.83%)

   Second quartile                                                                      202,685 (26.76%)

   Third quartile                                                                       178,671 (23.59%)

   Fourth quartile                                                                      150,090 (19.82%)

  **Hospital Bed size**                                                                 

   Small                                                                                103,493 (13.58%)

   Medium                                                                               210,779 (27.65%)

   Large                                                                                448,050 (58.77%)

  **Hospital Region**                                                                   

   Northeast                                                                            161,462 (21.10%)

   Midwest                                                                              182,787 (23.88%)

   South                                                                                277,347 (36.24%)

   West                                                                                 143,745 (18.78%)

  Outcomes                                                                              

  **Total Hospital Charge, Mean (SE); median, U.S. \$**                                 23,876 (314); 12,196

  **Discharge Status**                                                                  

   Inpatient                                                                            161,826 (23.66%)

   Home                                                                                 522,243 (76.34%)

  **Length of Hospital Stay, Mean (SE); median**                                        3.6 (0.02); 1.9

  **Length of Hospital Stay category, days**[\*\*\*](#t001fn003){ref-type="table-fn"}   

   ≤3                                                                                   571,442 (73.10%)

   \>3                                                                                  210,325 (26.90%)

  **Died during hospitalization**                                                       18,394 (2.36%)

  Discharge Against Medical Advice                                                      77,323 (9.89%)
  -----------------------------------------------------------------------------------------------------------------------------------------------------

\*Opioid drug abuse hospitalizations included those with primary diagnostic code of the following: 304.0x, 304.7x, 305.5x, 965.0x, E850.0, E935.0, F111.xxx, F112.xxx, T40.1X1x-4x,T40.2X1x-4x, or T40.3X1x-4x We excluded hospitalizations with ICD-9-CM diagnostic or procedure codes corresponding to drug/alcohol counseling and rehabilitation/detoxification including diagnostic codes 304.03, 304.73, 305.53, F11.11xx, or F11.21xx and procedure codes 94.45, 94.64--94.69, HZ2xxxx-3xxxx, HZ4xxxx, HZ5xxxx-6xxxx, HZ81xxx-82xxx, HZ84xxx-86xxx, HZ88xxx-89xxx, HZ91xxx-92xxx, HZ94xxx-96xxx, HZ98xxx-99xxx.

\*\* Based on N, actual = 161,056

\*\*\*The median hospital stay for all NIS hospitalizations was 3 days, which was used to categorize this variable

Characteristics of OUD-hospitalizations and outcomes by region {#sec013}
--------------------------------------------------------------

We found that compared to the Northeast, people with OUD-hospitalizations in the other 3 U.S. regions were more likely to be older, female, have Deyo-Charlson comorbidity index score ≥2, have Medicare, be admitted to a hospital with large bed size; and less likely to be White, have Medicaid, be in the highest income quartile, be admitted to urban, teaching hospital ([Table 2](#pone.0229174.t002){ref-type="table"}).

10.1371/journal.pone.0229174.t002

###### OUD-hospitalization characteristics by U.S. hospital region.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  N (%), unless specified otherwise                                                         Northeast\             Midwest\               South N = 277,347 (36.24%)   West\
                                                                                            N = 161,462 (21.10%)   N = 182,787 (23.88%)                                N = 143,745 (18.78%)
  ----------------------------------------------------------------------------------------- ---------------------- ---------------------- ---------------------------- ----------------------
  **Age category, in years**[\*](#t002fn002){ref-type="table-fn"}                                                                                                      

   \<34                                                                                     57,795 (35.80%)        60,776 (33.25%)        88,103 (31.77%)              35,534(24.75%)

   34--45                                                                                   41,284 (25.75%)        45,645 (24.97%)        58,727 (21.18%)              28,298 (19.71%)

   \>45--55                                                                                 32,326 (20.02%)        37,932 (20.75%)        60,897 (21.96%)              32,793 (22.84%)

   \>55                                                                                     30,046 (18.61%)        38,424 (21.02%)        69,564 (25.09%)              46,953 (32.79%)

  **Sex**[\*](#t002fn002){ref-type="table-fn"}                                                                                                                         

   Male                                                                                     97,330 (60.30%)        95,865 (52.45%)        136,533 (49.24%)             69,581 (48.57%)

   Female                                                                                   64,087 (39.70%)        86,912 (47.55%)        140,751 (50.76%)             73,679 (51.43%)

  **Race**[\*](#t002fn002){ref-type="table-fn"}                                                                                                                        

   White                                                                                    113,563 (70.34%)       99,314 (54.33%)        204,933 (73.89%)             94,260 (65.59%)

   Black                                                                                    19,306 (11.96%)        16,676 (9.12%)         22,900 (8.26%)               6,471 (4.50%)

   Hispanic                                                                                 17,193 (10.65%)        2,290 (1.25%)          12,583 (4.54%)               15,444 (10.75%)

   Other/missing                                                                            11,396 (7.06%)         64,502 (35.29%)        36,931 (13.32%)              27,545 (19.17%)

  **Deyo-Charlson Score**[\*](#t002fn002){ref-type="table-fn"}                                                                                                         

   0                                                                                        103,460 (64.08%)       110,104 (60.24%)       165,652 (59.73%)             80,599 (56.07%)

   1                                                                                        32,067 (19.86%)        40,668 (22.25%)        58,226 (20.99%)              30,810 (21.43%)

   ≥2                                                                                       25,935 (16.06%)        32,015 (17.51%)        53,469 (19.28%)              32,336 (22.50%)

  **Hospital Location/Teaching**[\*](#t002fn002){ref-type="table-fn"}                                                                                                  

   Rural                                                                                    11,938 (7.39%)         21,216 (11.73%)        42,343 (15.30%)              12,555 (8.76%)

   Urban nonteaching                                                                        46,363 (28.71%))       68,256 (37.73%)        122,488 (44.26%)             78,103 (54.52%)

   Urban teaching                                                                           103,161 (63.89%)       91,414 (50.54%)        111,896 (40.44%)             52,590 (36.71%)

  **Insurance**[\*](#t002fn002){ref-type="table-fn"}                                                                                                                   

   Medicaid                                                                                 1,347,595 (52.11%)     668,596 (41.73%)       682,726 (30.95%)             455,310 (32.37%)

   Medicare                                                                                 389,372 (15.06%)       324,596 (20.26%)       510,635 (23.15%)             366,844 (26.00%)

   Other                                                                                    83,110 (3.21%)         88,816 (5.54%)         159,076 (7.21%)              117,542 (8.33%)

   Private                                                                                  430,734 (16.65%)       339,809 (21.21%)       422,857 (19.17%)             337,234 (23.90%)

   Self                                                                                     335,482 (12.97%)       180,332 (11.26%)       430,700 (19.52%)             134,087 (9.50%)

  **Income Category**[\*](#t002fn002){ref-type="table-fn"}                                                                                                             

   First quartile                                                                           34,756 (22.71%)        56,282 (31.30%)        99,603 (36.93%)              27,866 (20.20%)

   Second quartile                                                                          32,055 (20.95%)        53,517 (29.57%)        78,213 (29.00%)              34,244 (24.82%)

   Third quartile                                                                           38,096 (24.89%)        41,539 (22.95%)        56,275 (20.87%)              40,108 (29.07%)

   Fourth quartile                                                                          48,125 (31.45%)        29,658 (16.39%)        35,592 (13.20%)              35,765 (25.92%)

  **Hospital Bed size**[\*](#t002fn002){ref-type="table-fn"}                                                                                                           

   Small                                                                                    28,650 (17.74%)        24,854 (13.74%)        34,092 (12.32%)              15,897 (11.10%)

   Medium                                                                                   48,136 (29.81%)        43,233 (23.90%)        81,264 (29.37%)              38,146 (26.63%)

   Large                                                                                    84,676 (52.44%)        112,799 (62.36%)       161,370 (58.31%)             89,205 (62.27%)

  **Outcomes**                                                                                                                                                         

  **Discharge Status**[\*](#t002fn002){ref-type="table-fn"}                                                                                                            

   Inpatient                                                                                31,564 (24.24%)        35,809 (22.27%)        61,265 (24.56%)              29,761 (22.99%)

   Home                                                                                     98,658 (75.76%)        125,022 (77.74%)       188,208 (75.44%)             99,695 (77.01%)

  **Length of Hospital Stay category, days**[\*](#t002fn002){ref-type="table-fn"}                                                                                      

   ≤3                                                                                       103,047 (63.82%)       132,027 (72.73%)       183,251 (66.07%)             98,878 (68.79%)

   \>3                                                                                      58,415 (36.18%)        50,760 (27.77%)        94,096 (33.93%)              44,867 (31.21%)

  **Length of Hospital Stay, Mean (SE)**[\*](#t002fn002){ref-type="table-fn"}**; median**   4.1 (0.07); 2.0        3.2 (0.05); 1.8        3.7 (0.03); 1.9              3.6 (0.04); 1.8

  **Total Hospital Charges, Mean (SE)**[\*](#t002fn002){ref-type="table-fn"}**; median**    24,463 (619); 11,418   17,828 (711); 9,714    23,134 (275); 12,361         34,403 (529); 18,852

  **Died during hospitalization**[\*](#t002fn002){ref-type="table-fn"}                      4,083 (2.54%)          3,986 (2.18%)          6,368 (2.30%)                3,857 (2.69%)

  Discharge Against Medical Advice[\*](#t002fn002){ref-type="table-fn"}                     26,534 (16.43%)        17,651 (9.66%)         21,246 (7.66%)               9,687 (6.74%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Total N, projected for OUD-hospitalization = 781,767

\*Statistically significantly with a p-value \<0.001

Compared to the Northeast, we found that a slightly lower proportion of OUD hospitalizations in the other 3 U.S. regions had discharge to non-home settings, had hospital length of stay \>3 days or left against medical advice (all with p-value \<0.001; [Table 2](#pone.0229174.t002){ref-type="table"}). Mean hospital stay was longest in the Northeast; mean hospital charges were the highest in the West followed by Northeast. Differences in in-hospital mortality were also statistically significant, but small in magnitude.

Outcomes of opioid use disorder hospitalizations by age, sex and race {#sec014}
---------------------------------------------------------------------

We noted the people with older age \>55 and females with OUD-hospitalization were significantly more likely than younger people and males to be discharged to non-home settings, have hospital charges higher than the median, or hospital stay \>3 days ([S1 Table](#pone.0229174.s001){ref-type="supplementary-material"}). Whites were more likely to be discharged to non-home settings compared to all other race/ethnicities. Differences in mortality by age, sex and race were small.

Time-trends in opioid use disorder hospitalization and associated mortality and healthcare utilization {#sec015}
------------------------------------------------------------------------------------------------------

OUD hospitalizations were 59.8 per 100,000 of all NIS hospitalizations in the U.S. with any diagnosis in 1998--2000, which increased steadily over the study period to 190.7 per 100,000 NIS hospitalizations in 2015--16, i.e. a 219% increase, leading to a rate increase of 3.2-fold ([Table 3](#pone.0229174.t003){ref-type="table"}; [Fig 1](#pone.0229174.g001){ref-type="fig"}). The mortality rate for OUD hospitalization was 1.2 per 100,000 NIS hospitalizations in the U.S. in 1998--2000 that increased 5-times to 5.9 per 100,000 NIS hospitalizations in 2015--16 ([Table 3](#pone.0229174.t003){ref-type="table"}).

10.1371/journal.pone.0229174.t003

###### Time-trends in OUD hospitalization and mortality rates from 1998 to 2016 and the comparative non-OUD mortality rates.
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                   Total NIS claims   OUD claims   OUD deaths   OUD claims Per 100K total NIS claims   OUD Death rate Per 100K NIS claims   OUD Death rate per 1k primary OUD claims   Comparative Death rate per 1k Non-OUD claims
  ---------------- ------------------ ------------ ------------ -------------------------------------- ------------------------------------ ------------------------------------------ ----------------------------------------------
  **1998--2000**   103,665,051        62,010       1,226        59.82                                  1.18                                 19.77                                      23.79
  **2001--2002**   72,617,381         53,176       1,002        73.23                                  1.38                                 18.84                                      22.18
  **2003--2004**   74,571,583         63,853       1,228        85.63                                  1.65                                 19.23                                      20.88
  **2005--2006**   75,919,595         66,923       1,350        88.15                                  1.78                                 20.17                                      19.73
  **2007--2008**   76,366,797         78,541       1,524        102.85                                 2.00                                 19.40                                      19.07
  **2009--2010**   75,086,597         97,611       2,149        130.00                                 2.86                                 22.02                                      18.24
  **2011--2012**   73,447,261         112,428      2,445        153.07                                 3.33                                 21.75                                      18.07
  **2013--2014**   70,956,610         110,985      3,255        156.41                                 4.59                                 29.33                                      18.93
  **2015--2016**   71,445,363         136,240      4,215        190.69                                 5.90                                 30.94                                      19.05

All rates are expressed per 100k or per 1k claims or hospitalizations

The last column represents the death rate in all NIS hospitalizations except OUD hospitalizations.

![Time-trend in OUD hospitalization rate per 100,000 NIS claims from 1998 to 2016.\
X-axis represents time-periods from 1998--2000 to 2015--16. Y-axis shows primary OUD hospitalization rates per 100,00 NIS claims.](pone.0229174.g001){#pone.0229174.g001}

Among the OUD hospitalizations, the mortality rate increased from 19.8 per 1,000 OUD hospitalizations in 1998--2000 to 30.9 per 1,000 OUD hospitalizations in 2015--16 ([Table 3](#pone.0229174.t003){ref-type="table"}). In comparison, mortality rate decreased for non-OUD hospitalizations over the same period from 23.8 to 19 per 1,000 non-OUD hospitalizations ([Fig 2](#pone.0229174.g002){ref-type="fig"}). Time-related increase in OUD hospitalizations and associated mortality was seen in all age groups, both sexes and in both white and non-white race/ethnicity (**data available on request**).

![Comparison of OUD vs. non-OUD death rates over the study period from 1998 to 2016.\
X-axis represents time-periods from 1998--2000 to 2015--16. Y-axis shows the in-hospital death rates per 1k among primary OUD hospitalizations (hashed bars) and among all NIS hospitalizations except OUD (solid bars).](pone.0229174.g002){#pone.0229174.g002}

Time-trends in OUD hospitalization associated healthcare utilization showed an increase over the study period, with the mean (median) total hospital charges increased from \$8,261 (\$4,339) to \$32,792 (\$18,244; [Table 3](#pone.0229174.t003){ref-type="table"}). In contrast, we saw little change in mean (median) length of hospital stay from 3.2 days (1.6) to 3.9 days (2.2) over the study period and no change in the proportion discharged to home, i.e., 80% in 1998--2000 versus 80% in 2015--16 ([Table 4](#pone.0229174.t004){ref-type="table"}).

10.1371/journal.pone.0229174.t004

###### Time-trends in healthcare utilization outcomes for OUD Hospitalizations from 1998 to 2016.
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               Total hospital charges, US \$   Discharged home   Length of Hospital Stay, days
  ------------ ------------------------------- ----------------- -------------------------------
  1998--2000   8,261 (601); 4,339              39,726 (80%)      3.2 (0.13); 1.6
  2001--2002   11,101 (729); 5,676             33,074 (75%)      3.4 (0.07); 1.8
  2003--2004   13,830 (1,003); 7,064           41,975 (76%)      3.4 (0.12); 1.7
  2005--2006   17,756 (557); 9,573             44,941 (75%)      3.6 (0.07); 1.8
  2007--2008   22,767 (563); 11,912            52,091 (74%)      3.7 (0.08); 1.8
  2009--2010   24,844 (648); 13,387            65,752 (75%)      3.7 (0.06); 1.9
  2011--2012   28,210 (573); 15,634            75,989 (75%)      3.7 (0.05); 1.9
  2013--2014   32,666 (477); 18,188            73,985 (75%)      3.8 (0.04); 1.9
  2015--2016   32,792 (586); 18,244            94,710 (80%)      3.9 (0.05); 2.2

SE, standard error; US \$, US dollar

Multivariable-adjusted predictors of healthcare utilization and inpatient mortality in people admitted with opioid use disorder {#sec016}
-------------------------------------------------------------------------------------------------------------------------------

In the multivariable-adjusted analysis, compared to age \<34 years, older age was associated with a higher risk of hospital charges above the median and the length of hospital stay \>3 days and a slightly higher risk of discharge to a rehabilitation facility ([Table 5](#pone.0229174.t005){ref-type="table"}). Higher Deyo-Charlson score was associated with higher hospital charges, a longer length of hospital stay, and higher inpatient mortality ([Table 5](#pone.0229174.t005){ref-type="table"}). Women had 26% higher odds and Blacks 31% lower odds of discharge to a rehabilitation facility, compared to men and Whites, respectively.

10.1371/journal.pone.0229174.t005

###### Predictors of healthcare utilization for people with an OUD hospitalization in the U.S.
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                                    Hospital charge above the median[\*](#t005fn001){ref-type="table-fn"}   Length of hospital stay \> 3 days   Discharge to inpatient facility   In-hospital Mortality
  --------------------------------- ----------------------------------------------------------------------- ----------------------------------- --------------------------------- -----------------------
  Age category                                                                                                                                                                    
   \<34 years                       Ref                                                                     Ref                                 Ref                               Ref
   34--45 years                     **1.24 (1.20, 1.28)**                                                   **1.06 (1.02, 1.09)**               **1.05 (1.01, 1.09)**             0.95 (0.86, 1.04)
   \>45--55 years                   **1.61 (1.55, 1.66)**                                                   **1.21 (1.17, 1.26)**               1.02 (0.98, 1.06)                 **0.82 (0.74, 0.91)**
   \>55 years                       **1.72 (1.66, 1.79)**                                                   **1.41 (1.36, 1.47)**               **1.16 (1.11, 1.21)**             **0.74 (0.66, 0.83)**
  Sex                                                                                                                                                                             
   Male                             Ref                                                                     Ref                                 Ref                               Ref
   Female                           0.97 (0.95, 0.99)                                                       1.01 (0.99, 1.04)                   **1.26 (1.23, 1.30)**             **0.75 (0.70, 0.81)**
  Race                                                                                                                                                                            
   White                            Ref                                                                     Ref                                 Ref                               Ref
   Black                            **0.87 (0.84, 0.91)**                                                   **0.84 (0.81, 0.88)**               **0.69 (0.65, 0.73)**             **0.67 (0.59, 0.77)**
   Hispanic                         **1.13 (1.07, 1.18)**                                                   **0.91 (0.86, 0.95)**               **0.83 (0.78, 0.88)**             **0.76 (0.66, 0.88)**
   Other/missing                    **0.84 (0.82, 0.87)**                                                   **0.77 (0.74, 0.79)**               **0.88 (0.85, 0.91)**             **0.90 (0.82, 0.99)**
  Deyo-Charlson comorbidity Score                                                                                                                                                 
   0                                Ref                                                                     Ref                                 Ref                               Ref
   1                                **1.57 (1.53, 1.62)**                                                   **1.35 (1.31, 1.39)**               **0.92 (0.89, 0.95)**             **1.84 (1.69, 2.02)**
   ≥2                               **2.16 (2.09, 2.23)**                                                   **1.91 (1.84, 1.97)**               **1.05 (1.01, 1.09)**             **2.46 (2.23, 2.72)**
  Insurance                                                                                                                                                                       
   Private                          Ref                                                                     Ref                                 Ref                               Ref
   Medicaid                         0.97 (0.94, 1.00)                                                       **1.06 (1.03, 1.10)**               **0.82 (0.79, 0.85)**             **1.17 (1.06, 1.29)**
   Medicare                         **1.15 (1.11, 1.19)**                                                   **1.11 (1.07, 1.15)**               **1.20 (1.16, 1.25)**             **0.79 (0.71, 0.88)**
   Other                            **1.08 (1.03, 1.14)**                                                   1.06 (1.00, 1.12)                   **0.89 (0.84, 0.95)**             0.98 (0.83, 1.15)
   Self                             **1.04 (1.01, 1.08)**                                                   **0.72 (0.69, 0.75)**               **0.75 (0.72, 0.79)**             **1.24 (1.11, 1.38)**
  Income category                                                                                                                                                                 
   First quartile                   **0.86 (0.83, 0.89)**                                                   **1.06 (1.02, 1.10)**               **0.79 (0.76, 0.83)**             0.96 (0.87, 1.06)
   Second quartile                  **0.86 (0.83, 0.89)**                                                   1.00 (0.96, 1.03)                   **0.88 (0.85, 0.92)**             0.97 (0.88, 1.07)
   Third quartile                   **0.93 (0.90, 0.96)**                                                   1.02 (0.98, 1.06)                   **0.92 (0.89, 0.96)**             0.98 (0.89, 1.08)
   Fourth quartile                  Ref                                                                     Ref                                 Ref                               Ref
  Hospital region                                                                                                                                                                 
   Northeast                        Ref                                                                     Ref                                 Ref                               Ref
   Midwest                          **0.58 (0.56, 0.60)**                                                   **0.71 (0.69, 0.74)**               **0.88 (0.85, 0.92)**             0.91 (0.82, 1.01)
   South                            **0.90 (0.88, 0.93)**                                                   **0.93 (0.90, 0.97)**               **0.95 (0.91, 0.98)**             1.00 (0.91, 1.11)
   West                             **1.66 (1.60, 1.72)**                                                   **0.75 (0.72, 0.77)**               **0.82 (0.78, 0.85)**             **1.16 (1.04, 1.29)**
  Hospital teaching status                                                                                                                                                        
   Rural                            Ref                                                                     Ref                                 Ref                               Ref
   Urban nonteaching                **2.28 (2.19, 2.37)**                                                   **1.42 (1.36, 1.48)**               0.98 (0.94, 1.03)                 **1.57 (1.36, 1.82)**
   Urban teaching                   **2.42 (2.32, 2.52)**                                                   **1.81 (1.74, 1.89)**               **0.84 (0.80, 0.87)**             **2.17 (1.88, 2.50)**
  Hospital bed size                                                                                                                                                               
   Small                            Ref                                                                     Ref                                 Ref                               Ref
   Medium                           **1.35 (1.30, 1.40)**                                                   **1.08 (1.04, 1.12)**               1.02 (0.98, 1.07)                 **1.25 (1.11, 1.40)**
   Large                            **1.53 (1.48, 1.58)**                                                   **1.24 (1.20, 1.29)**               1.00 (0.96, 1.04)                 **1.19 (1.07, 1.32)**

\*Total hospital charge were categorized as above or below the median for each year individually

We found that women had 25% lower odds of inpatient mortality than men, blacks had 33% lower odds of mortality than whites and older age was associated with higher inpatient mortality. The models for hospital charges, length of stay, and inpatient mortality also showed better outcomes for rural hospitals compared with both urban teaching and urban non-teaching hospitals. Compared to the hospitals in the Northeast U.S., those in the Midwest and the South had lower hospital charges, shorter length of stay, and lower odds of discharge to non-home settings. Lower income was associated with lower hospital charges and lower odds of discharge to non-home settings ([Table 5](#pone.0229174.t005){ref-type="table"}).

Discussion {#sec017}
==========

We performed a longitudinal study of OUD hospitalizations over a 19-year period from 1998 to 2016, the most recent year of publicly available NIS data. We examined the time-trends in OUD hospitalizations and associated healthcare utilization outcomes and mortality, and their predictors. Our multivariable-adjusted models identified several factors independently associated with each healthcare utilization and in-hospital mortality, while all the other factors shown were adjusted for in the analyses. Several findings of this study merit further discussion.

The OUD hospitalizations in the U.S. increased steadily from 62,010 in 1998--2000 to 136,240 in 2015--2016, the most recent period with available data. We noted a 219% increase in OUD hospitalizations, compared to the baseline from 1998--2000. The continued rise in OUD hospitalizations in the U.S. is of concern. State and federal agencies have implemented several policies for OUD and various programs to reduce related morbidity \[[@pone.0229174.ref010],[@pone.0229174.ref013]--[@pone.0229174.ref016]\]. This increasing trend in OUD hospitalizations in the U.S. confirms the impact of OUD epidemic on the healthcare system, and describes the magnitude of the problem. These findings are also consistent with an increasing OUD in delivery hospitalizations to 2014 \[[@pone.0229174.ref017]\].

The death rate for OUD hospitalizations was 1.2 per 100,000 NIS hospitalizations in 1998--2000 that increased 5-times to 5.9 per 100,000 NIS hospitalizations in 2015--16. The increase in the OUD hospitalization mortality rate continued through the most recent study period, 2015--16. There was an increase of 77% between 2011--2012 to 2015--16. This is consistent with national CDC estimates of rapidly increasing OUD-related deaths, noted to be 28,647, 33,091 and 42,249 in 2014, 2015 and 2016, respectively \[[@pone.0229174.ref001],[@pone.0229174.ref006]\]. The 47% increase in OUD-related mortality from 2014 to 2016 was alarming \[[@pone.0229174.ref006]\].

Compared to mortality rate in the general population with hospitalization, OUD-related mortality rates were 0.8 times in 1998--2000, but rose to 1.6 times higher in 2015--2016. This indicates worsening of the mortality outcome in OUD-related hospitalizations over time, relative to all other hospitalizations in the U.S. This might be related to a higher severity of opioid abuse, a reduction in access to care or higher associated psychiatric or medical comorbidity over time. These hypotheses need further examination.

In unadjusted comparisons, we noted the OUD hospitalizations in people with older age \>55, females and Northeast U.S. region had higher healthcare utilization; OUD hospitalizations in Northeast were also associated with higher proportion of people leaving against medical advice. Whites had higher rate of discharge to non-home settings after OUD hospitalizations compared to other race/ethnicities. Mortality rates were only slightly different by any of these characteristics. We also found interesting differences in patient characteristics by U.S. region in OUD hospitalizations.

The implementation of effective policy and public health programs in the U.S. has the potential to reverse the trend in OUD hospitalizations in the near future \[[@pone.0229174.ref009],[@pone.0229174.ref010],[@pone.0229174.ref013]--[@pone.0229174.ref016],[@pone.0229174.ref018]--[@pone.0229174.ref020]\]. Strategies and programs to reduce OUD and improve OUD outcomes are being developed. Examples include a system-wide organizational opioid stewardship program (OSP) that was associated with a reduction in opioid morbidity \[[@pone.0229174.ref021]\]. A combined implementation of mandated provider review of state-run prescription drug monitoring program and pain clinic laws reduced opioid amounts prescribed by 8% and prescription opioid overdose death rates by 12% \[[@pone.0229174.ref022]\]. Telemedicine has the potential to improve the provision of evidence-based medication-assisted treatment for OUD \[[@pone.0229174.ref023]\]. The use of buprenorphine and methadone maintenance treatment after non-fatal opioid overdose reduced all-cause and opioid-related mortality \[[@pone.0229174.ref024]\]. This finding is supported by a systematic review and meta-analysis of 19 studies with 138,716 people treated with either methadone or buprenorphine for opioid dependence \[[@pone.0229174.ref025]\]. Thus, effective strategies exist to reduce the OUD-related morbidity and mortality.

We examined important patient/clinical characteristics associated with OUD hospitalization related healthcare utilization and mortality. Older age, White race, a higher Deyo-Charlson score and female sex were each associated with worse healthcare utilization outcomes or mortality related to index OUD hospitalization. A previous CDC analysis of drug overdose deaths (prescription opioids and heroin were the main causes) using the 2013 and 2014 national data found that age-adjusted mortality rates for Whites, Blacks and Hispanics were 19, 10.5 and 6.7 per 100,000 \[[@pone.0229174.ref003]\]. In a study of OUD-hospitalization mortality, Whites, ages 50--64, Medicare beneficiaries with disabilities, and residents of lower-income areas were noted to have higher odds of opioid/heroin poisoning \[[@pone.0229174.ref026]\]. These studies provide one potential reason for higher mortality in Whites and are consistent with our observation of an independent association of White race with higher mortality during OUD-hospitalization, adjusted for age, sex, insurance, income, comorbidity, hospital region (rural/urban) and teaching status, location or bed size. Future studies are needed to assess the other underlying causes for higher mortality in Whites with OUD-hospitalizations.

Our observation of the association of male sex with higher inpatient mortality of OUD-hospitalization extends similar observations in people who underwent elective total joint replacement \[[@pone.0229174.ref027]\] or with pharmaceutical opioid related overdose deaths \[[@pone.0229174.ref028]\]. We also noted differences by region and by hospital characteristics in these outcomes, which extend similar findings for opioid and heroin-related overdose hospitalizations \[[@pone.0229174.ref008]\] to OUD-related hospitalizations.

Our study findings must be interpreted considering study limitations. Misclassification bias is possible, since we used diagnostic codes for the identification of the study cohort and comorbidities. Our observational cohort study design puts this study at the potential risk of residual confounding for the predictors of healthcare utilization and mortality outcomes; we adjusted for multiple covariates and confounders to reduce the risk of confounding bias. We assessed hospital charges, which are usually inflated and do not reflect the actual cost of the hospitalization. Due to the lack of cause of death data in the NIS, we are unable to comment on whether the causes of death changed over time, were attributed to OUD or related disorder (hepatitis C, HIV, endocarditis, valvular disease) or differed by factors significantly associated with higher mortality. Longer-term studies of mortality up to 4 years after OUD hospitalization found that both opioid use and physical comorbidities contributed to mortality \[[@pone.0229174.ref029],[@pone.0229174.ref030]\].

Our study has many strengths. We used the U.S. NIS, a national dataset that makes our results generalizable to the general U.S. population. We used two decades of data to examine the time-trends in OUD hospitalization, another study strength.

Conclusions {#sec018}
===========

In conclusion, we found increasing rates of OUD hospitalizations and OUD mortality rates from 1998 to 2016. These time-trends are concerning, given the alarmingly high rates of associated mortality and no trends of a slow-down or decline. We identified factors associated with healthcare utilization and mortality outcomes for OUD hospitalizations. Future studies need to examine the most effective strategies to reduce OUD hospitalizations and associated mortality and healthcare utilization.

Supporting information {#sec019}
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###### OUD-hospitalization outcomes by age, sex and race.
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Click here for additional data file.
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Response: Thank you.

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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Response: Thank you

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors used 781,000+ hospital records from a National Institutional sample of hospitalizations for the period 1998 through 2016 to calculate rates of hospitalization by age race and gender for Opioid overdose Hospitalizations and in hospital mortality noting that the rates increase from 59.8 per 100,00 to 190 per 100,000 over the 18 years period.

They indicate that on a national basis this is one of the first and only papers to chronicle this information which makes it unique. They examined healthcare utilization outcomes over time. Can they move this forward by examining some of the regional differences in west, midwest, Northeast and south regions , are these all the same with regard to white and black and by age?

Response: We have provided this as a new table as suggested, and have these results to results and discussion sections.

Table 2. OUD-hospitalization characteristics by U.S. hospital region

N (%), unless specified otherwise Northeast

N=161,462 (21.10%)

Midwest

N=182,787 (23.88%) South N=277,347 (36.24%) West

N=143,745 (18.78%)

Age category, in years\*

\<34 57,795 (35.80%) 60,776 (33.25%) 88,103 (31.77%) 35,534(24.75%)

34 - 45 41,284 (25.75%) 45,645 (24.97%) 58,727 (21.18%) 28,298 (19.71%)

\>45 - 55 32,326 (20.02%) 37,932 (20.75%) 60,897 (21.96%) 32,793 (22.84%)

\>55 30,046 (18.61%) 38,424 (21.02%) 69,564 (25.09%) 46,953 (32.79%)

Sex\*

Male 97,330 (60.30%) 95,865 (52.45%) 136,533 (49.24%) 69,581 (48.57%)

Female 64,087 (39.70%) 86,912 (47.55%) 140,751 (50.76%) 73,679 (51.43%)

Race\*

White 113,563 (70.34%) 99,314 (54.33%) 204,933 (73.89%) 94,260 (65.59%)

Black 19,306 (11.96%) 16,676 (9.12%) 22,900 (8.26%) 6,471 (4.50%)

Hispanic 17,193 (10.65%) 2,290 (1.25%) 12,583 (4.54%) 15,444 (10.75%)

Other/missing 11,396 (7.06%) 64,502 (35.29%) 36,931 (13.32%) 27,545 (19.17%)

Deyo-Charlson Score\*

0 103,460 (64.08%) 110,104 (60.24%) 165,652 (59.73%) 80,599 (56.07%)

1 32,067 (19.86%) 40,668 (22.25%) 58,226 (20.99%) 30,810 (21.43%)

≥2 25,935 (16.06%) 32,015 (17.51%) 53,469 (19.28%) 32,336 (22.50%)

Hospital Location/Teaching\*

Rural 11,938 (7.39%) 21,216 (11.73%) 42,343 (15.30%) 12,555 (8.76%)

Urban nonteaching 46,363 (28.71%)) 68,256 (37.73%) 122,488 (44.26%) 78,103 (54.52%)

Urban teaching 103,161 (63.89%) 91,414 (50.54%) 111,896 (40.44%) 52,590 (36.71%)

Insurance\*

Medicaid 1,347,595 (52.11%) 668,596 (41.73%) 682,726 (30.95%) 455,310 (32.37%)

Medicare 389,372 (15.06%) 324,596 (20.26%) 510,635 (23.15%) 366,844 (26.00%)

Other 83,110 (3.21%) 88,816 (5.54%) 159,076 (7.21%) 117,542 (8.33%)

Private 430,734 (16.65%) 339,809 (21.21%) 422,857 (19.17%) 337,234 (23.90%)

Self 335,482 (12.97%) 180,332 (11.26%) 430,700 (19.52%) 134,087 (9.50%)

Income Category\*

First quartile 34,756 (22.71%) 56,282 (31.30%) 99,603 (36.93%) 27,866 (20.20%)

Second quartile 32,055 (20.95%) 53,517 (29.57%) 78,213 (29.00%) 34,244 (24.82%)

Third quartile 38,096 (24.89%) 41,539 (22.95%) 56,275 (20.87%) 40,108 (29.07%)

Fourth quartile 48,125 (31.45%) 29,658 (16.39%) 35,592 (13.20%) 35,765 (25.92%)

Hospital Bed size\*

Small 28,650 (17.74%) 24,854 (13.74%) 34,092 (12.32%) 15,897 (11.10%)

Medium 48,136 (29.81%) 43,233 (23.90%) 81,264 (29.37%) 38,146 (26.63%)

Large 84,676 (52.44%) 112,799 (62.36%) 161,370 (58.31%) 89,205 (62.27%)

Outcomes

Discharge Status\*

Inpatient 31,564 (24.24%) 35,809 (22.27%) 61,265 (24.56%) 29,761 (22.99%)

Home 98,658 (75.76%) 125,022 (77.74%) 188,208 (75.44%) 99,695 (77.01%)

Length of Hospital Stay category, days\*

≤3 103,047 (63.82%) 132,027 (72.73%) 183,251 (66.07%) 98,878 (68.79%)

\>3 58,415 (36.18%) 50,760 (27.77%) 94,096 (33.93%) 44,867 (31.21%)

Died during hospitalization\* 4,083 (2.54%) 3,986 (2.18%) 6,368 (2.30%) 3,857 (2.69%)

Discharge Against Medical Advice\* 26,534 (16.43%) 17,651 (9.66%) 21,246 (7.66%) 9,687 (6.74%)

Total N, projected for OUD-hospitalization = 781,767

\*Statistically significantly with a p-value \<0.001

Results

"Characteristics of OUD-hospitalizations and outcomes by Region

We found that compared to the Northeast, people with OUD-hospitalizations in the other 3 U.S. regions were more likely to be older, female, have Deyo-Charlson comorbidity index score ≥2, have Medicare, be admitted to a hospital with large bed size; and less likely to be White, have Medicaid, be in the highest income quartile, be admitted to urban, teaching hospital (Table 2).

Compared to the Northeast, we found that a slightly lower proportion of OUD hospitalizations in the other 3 U.S. regions had discharge to non-home settings, had hospital length of stay \>3 days or left against medical advice (all with p-value \<0.001; Table 2). Differences in in-hospital mortality were also statistically significant, but small in magnitude."

Discussion

"In unadjusted comparisons, we noted the OUD hospitalizations in people with older age \>55, females and Northeast U.S. region had higher healthcare utilization; OUD hospitalizations in Northeast were also associated with higher proportion of people leaving against medical advice. Whites had higher rate of discharge to non-home settings after OUD hospitalizations compared to other race/ethnicities. Mortality rates were only slightly different by any of these characteristics. We also found interesting differences in patient characteristics by U.S. region in OUD hospitalizations."

A geospatial map of rates or table would be helpful showing black , white Hospitalization rates as well as a regional difference map as opposed to a multivariate logistic regression which is interesting but does not show important nuances in time , person and place.

Much can be learned in the details of this study, Older white male rates of mortality and hospitalization have been detailed previously so presenting some of the details would prove to be important.

Response: We have provided these data as requested as a new appendix with regards to age, race and sex with time-trends. We have added text to results and discussion.

"Outcomes of OUD hospitalizations by age, sex and race

We noted the people with older age \>55 and females with OUD-hospitalization were significantly more likely than younger people and males to be discharged to non-home settings, have hospital charges higher than the median, or hospital stay \>3 days (Appendix 1). Whites were more likely to be discharged to non-home settings compared to all other race/ethnicities. Differences in mortality by age, sex and race were small.

Appendix 1. OUD-hospitalization outcomes by age, sex and race

N (%), unless specified otherwise % Discharged to non-home settings Total hospital charges

\>median Length of hospital stay \>3 days Died during hospitalization

Age category, in years

\<34 43,787 (21.05%) 73,411 (29.59%) 64,217 (25.89%) 5,963 (2.41%)

34 - 45 33,663 (22.38%) 63,307 (35.63%) 51,860 (29.18%) 4,284 (2.42%)

\>45 - 55 34.309 (23.05%) 76,215 (45.61%) 58,458 (34.98%) 3,903 (2.34%)

\>55 50,051 (28.33%) 99,568 (52.78%) 78,813 (41.78%) 4,229 (2.24%)

Sex

Male 73,108 (21.10%) 159,035 (39.00%) 127,738 (31.33%) 10,871 (2.67%)

Female 88,638 (26.29%) 153,372 (41.08%) 125,518 (33.62%) 7,523 (2.02%)

Race

White 116,236 (25.32%) 215,485 (41.40%) 173,431 (33.32%) 12,770 (2.46%)

Black 10,004 (17.57%) 26,722 (40.57%) 22,691 (34.45%) 1,349 (2.05%)

Hispanic 7,759 (19.12%) 22,602 (46.93%) 15,801 (32.82%) 1,154 (2.40%)

Other/missing 27,822 (17.19%) 47,759 (32.46%) 41,489 (28.20%) 3,116 (2.12%)

A few questions, they indicate older white opioid hospitalizations fared worse that black and younger admits. Please comment on the reasons for this , specifically what were the causes of death among older white admits ; was this just an age phenomenon or was there something specific to region or urban /rural.

Response: We have more discussion related to this association noted between race and in-hospital mortality. However, due to non-availability of cause of death in this dataset, we are unable to provide further insights into causes of death. Since these analyses were adjusted for age, sex, insurance, income, comorbidity, hospital region (rural/urban) and teaching status, location or bed size, none of the noted difference by race can be attributed to these factors.

"A previous CDC analysis of drug overdose deaths (prescription opioids and heroin were the main causes) using the 2013 and 2014 national data found that age-adjusted mortality rates for Whites, Blacks and Hispanics were 19, 10.5 and 6.7 per 100,000 \[3\]. This previous observation is consistent with our observation of an independent association of White race with higher mortality during OUD-hospitalization, adjusted for age, sex, insurance, income, comorbidity, hospital region (rural/urban) and teaching status, location or bed size. Future studies are needed to assess the underlying causes for higher mortality for Whites in OUD-hospitalizations."

Please show stratification by average days of hospitalization by age and gender and race.

Response: Please see the new table and response added in response to an earlier comment by the reviewer. The length of stay \>3 days seemed to more in older people, therefore the association of age with LOS was noted in OUD-hospitalization. We noted smaller differences in the length of hospitalization by sex and race.

OUD and old age can be linked to end stage cancer diagnoses, please provide the information of end of life related causes of death versus others.

Response: We do not have cause of death data in the NIS, therefore we can not definitively assess the cause of OUD-in-hospital death. As can be seen from the table above added per the reviewer request, most of the in-hospital mortality were in the younger people, i.e., 45% of deaths were in people \<45 years and 77% of the deaths were in people \<55 years. Therefore, it is unlikely that cancer is one of the main reasons for OUD-hospitalization associated death. It is more likely that OUD mortality is related to OUD- and associated complications, including medical complications.

How much of the co morbidity was opioid and drug related, aka, Hepatitis C, HIV and myocardial endocarditis and valvular disease?

Response: The NIS does not provide the cause of death, so we are unable to ascertain the attribution of death to medical comorbidities listed in the comment vs. the OUD itself. We have added this to the study limitations section.

"Due to the lack of cause of death data in the NIS, we are unable to comment on whether the causes of death changed over time, were attributed to OUD or related disorder (hepatitis C, HIV, endocarditis, valvular disease) or differed by factors significantly associated with higher mortality."

ALso the logistic regressions should be given more detail with tables shown. What was the median length of stay hospitalization for those under 55 and over 55?

This data set has the ability to show important ground breaking information .

Response: We have provided additional data as suggested in response to an earlier comment to show data by age, sex and race. This has been added as an appendix/table. In addition, we have added more detail to the results section related to the logistic regression results.

"In the multivariable-adjusted analysis, compared to age \<34 years, older age was associated with a higher risk of hospital charges above the median and the length of hospital stay \>3 days and a slightly higher risk of discharge to a rehabilitation facility (Table 4). Higher Deyo-Charlson score was associated with higher hospital charges, a longer length of hospital stay, and higher inpatient mortality (Table 4). Women had 26% higher odds and Blacks 31% lower odds of discharge to a rehabilitation facility, compared to men and Whites, respectively.

We found that women had 25% lower odds of inpatient mortality than men, blacks had 33% lower odds of mortality than whites and older age was associated with higher inpatient mortality. The models for hospital charges, length of stay, and inpatient mortality also showed better outcomes for rural hospitals compared with both urban teaching and urban non-teaching hospitals . Compared to the hospitals in the Northeast U.S., those in the Midwest and the South had lower hospital charges, shorter length of stay, and lower odds of discharge to non-home settings. Lower income was associated with lower hospital charges and lower odds of discharge to non-home settings (Table 4)."

Discussion

"We performed a longitudinal study of OUD hospitalizations over a 19-year period from 1998 to 2016, the most recent year of publicly available NIS data. We examined the time-trends in OUD hospitalizations and associated healthcare utilization outcomes and mortality, and their predictors. Our multivariable-adjusted models identified several factors independently associated with each healthcare utilization and in-hospital mortality, while all the other factors shown were adjusted for in the analyses."

Reviewer \#2: The authors conducted an observational study form National Inpatient Sample, and showed an increase in OUD hospitalizations and associated inpatient mortality. Age, sex, race, and Deyo-Charlson comorbidity index are independent factors of healthcare utilization and mortality related to index OUD hospitalization.

Is there any data to support these independent factors associated with healthcare utilization and mortality related to OUD hospitalization?

Response: We have expanded the discussion related to associations we noted, that support our findings. In general, many findings were from smaller sub-cohorts of people with OUD.

"We examined important patient/clinical characteristics associated with OUD hospitalization related healthcare utilization and mortality. Older age, White race, a higher Deyo-Charlson score and female sex were each associated with worse healthcare utilization outcomes or mortality related to index OUD hospitalization. A previous CDC analysis of drug overdose deaths (prescription opioids and heroin were the main causes) using the 2013 and 2014 national data found that age-adjusted mortality rates for Whites, Blacks and Hispanics were 19, 10.5 and 6.7 per 100,000 \[3\]. In a study of OUD-hospitalization mortality, Whites, ages 50--64, Medicare beneficiaries with disabilities, and residents of lower-income areas were noted to have higher odds of opioid/heroin poisoning \[26\]. These studies provide one potential reason for higher mortality in Whites and are consistent with our observation of an independent association of White race with higher mortality during OUD-hospitalization, adjusted for age, sex, insurance, income, comorbidity, hospital region (rural/urban) and teaching status, location or bed size. Future studies are needed to assess the other underlying causes for higher mortality in Whites with OUD-hospitalizations.

Our observation of the association of male sex with higher inpatient mortality of OUD-hospitalization extends similar observations in people who underwent elective total joint replacement \[27\] or with pharmaceutical opioid related overdose deaths \[28\]. We also noted differences by region and by hospital characteristics in these outcomes, which extend similar findings for opioid and heroin-related overdose hospitalizations \[8\] to OUD-related hospitalizations."

Some comorbidity indices have been developed to measure and weigh the overall burden of comorbidities, for example, Charlson comorbidity index(CCI), Deyo CCI, Romano CCI. Is there any special reason for choosing Deyo CCI in this article.

Response: All versions of Charlson index have been validated, we agree whole-heartedly with the reviewer. We chose the Deyo-Charlson version as one of the commonly used versions of this comorbidity index.

Minor point: Table 4: The form after "Rural" is empty. Should it be "Ref"?

Response: Thank you for catching this error, we have fixed it.
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